Skip to content

Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023
22.09 +0.14 +0.64%
Live - 5344 symbols - heartbeat 132s ago · 2026-10-08 08:18
Pre-market 22.50 +1.86%
After-hours 22.38 +1.31%
Overnight 22.50 +1.86%
Market cap
1.95B
P/B
3.54
EPS
-2.29
Reader sentiment Are you bullish or bearish on MLYS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
    TipRanks · 2026/8/13
  • Rating change
    Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/5/19
  • Rating change
    Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56
    Market Newswire · 2026/8/13
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)
    TipRanks · 2026/5/7
  • Mineralys Therapeutics(MLYS.US) Director Sells US$3.01 Million in Common Stock
    Market Newswire · 2026/9/25
  • LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/8/12
  • Rating change
    TD Cowen Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating
    Market Newswire · 2026/5/7
  • Rating change
    A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56
    Market Newswire · 2026/5/8
  • Rating change
    Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/3/15
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/5/8
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/6/4
  • Form 144 | Mineralys Therapeutics(MLYS.US) Director Proposes to Sell 3.01 Million in Common Stocks
    Market Newswire · 2026/9/23
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • Rating change
    Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/4
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
    TipRanks · 2026/3/17
  • Rating change
    H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56
    Market Newswire · 2026/8/12
  • Rating change
    TD Cowen Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating
    Market Newswire · 2026/4/27
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/5/7
  • Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Wells Fargo
    TipRanks · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:18:44 · For reference only, not investment advice and not tailored to your situation.